失代偿
肝硬化
医学
补偿(心理学)
肝病
心脏失代偿
阶段(地层学)
心脏病学
慢性肝病
肝功能
内科学
病因学
胃肠病学
死亡率
疾病
心力衰竭
心理学
精神分析
古生物学
生物
作者
Zhimin He,B Q Wang,Hu You
出处
期刊:PubMed
日期:2019-12-20
卷期号:27 (12): 915-918
被引量:5
标识
DOI:10.3760/cma.j.issn.1007-3418.2019.12.002
摘要
Liver cirrhosis is the end stage of chronic liver disease and as the disease progresses to decompensated stage cirrhosis, the mortality rate of patients' increases significantly. The goal of controlling the etiology or treatment in decompensated stage cirrhosis is to improve the liver function of patients, stabilize the disease condition or reverse decompensation, reduce the recurrence of decompensated events and reduce the mortality rate. However, presently, there are few studies on the reversal of cirrhotic decompensation/ re-compensation. Moreover, the effect of prophylactic treatment on re-compensation, evaluation indicators and duration of re-compensation, structure of hepatic lobules and whether microvessels can be reconstructed are unclear, so require further research.肝硬化是慢性肝病的终末阶段,进展到肝硬化失代偿期患者病死率明显增加,控制病因或通过治疗改善患者肝功能,达到病情稳定或逆转失代偿,减少失代偿事件的再发生、降低病死率是肝硬化失代偿期治疗的目标;但是目前关于肝硬化失代偿的逆转/再代偿研究均较少,且关于预防性治疗对再代偿的影响、再代偿的评价指标、再代偿评估时间、肝小叶结构及微血管是否能重建等问题尚不清楚,需进一步研究。.
科研通智能强力驱动
Strongly Powered by AbleSci AI